GILD
Gilead Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Strong Buy"
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GILD
Gilead Sciences, Inc.
A biopharmaceutical company that develops therapeutics to treat viral, fungal, respiratory an cardiovascular diseases
Biological Technology
06/22/1987
01/24/1992
NASDAQ Stock Exchange
17,600
12-31
Common stock
333 Lakeside Drive, Foster City, California 94404
Development and sales of pharmaceuticals
Founded in Delaware on June 22, 1987, Gilead Sciences, Inc. is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of innovative medicines with unmet medical needs. The company's main areas of focus include viral diseases, inflammatory and fibrotic diseases, and oncology.
Earnings Call
Q2/2025
Estimate EPS1.96
Actual EPS2.01
Estimate Revenue6.96B
Actual Revenue7.08B
Gilead's Q2 2025: Unpacking Contradictions in Yeztugo Launch, Tariff Impacts, and PrEP Market Dynamics
Aug 07,2025 09:54
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS2.14
Actual EPS2.47
Estimate Revenue7.46B
Actual Revenue7.77B
Gilead's Q3 2025: Contradictions Emerge on PrEP Market Growth and Yeztugo Access Strategy
Oct 30,2025 09:18
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
GILD has released its 2025 Q3 earnings. EPS was reported at 2.47, versus the expected 2.14, beating expectations. The chart below visualizes how GILD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GILD has released its 2025 Q3 earnings report, with revenue of 7.77B, reflecting a YoY change of 2.97%, and net profit of 3.05B, showing a YoY change of 143.58%. The Sankey diagram below clearly presents GILD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
